WntResearch has received an approval on its patent application from the Canadian patent office for its drug candidate Box-5
WntResearch has received an approval from the Canadian patent office, Canadian Intellectual Property Office (CIPO), on its patent application for its drug candidate Box-5 and similar peptides for the treatment of malignant melanoma and gastric cancer.
Box-5 is currently in a pre-clinical development phase.
CEO Henrik Lawaetz’s comment: ”It is very good news that the Canadian patent office has approved our patent application for our drug candidate Box-5. We already have our main drug candidate Foxy-5 under patent protection in Canada, and that we now also have Box-5 protected is completely in line with our patent strategy.”
For further information, contact :
Henrik Lawaetz, CEO
WntResearch is developing a new type of cancer treatment based on pioneering research, which shows that the endogenous protein Wnt-5a plays a crucial role for tumour cells’ ability to relocate and spread inside the body. Most patients that die of cancer do so not due to the primary tumour, but due to metastasises and the need for a specific treatment to counteract metastasis is therefore in high demand.
WntResearch’s most advanced drug candidate Foxy-5 has in preclinical tests been shown to reduce tumour cells’ mobility and thereby counteract the occurrence of metastasis. The results from a completed phase 1-study show a favourable security profile and pharmacokinetics as well as early indications of biological activity. A phase 1b-study is currently ongoing in patients with cancer in colon, prostate and breast. WntResearch is a public company listed at AktieTorget in Stockholm, Sweden.
For further information: www.wntresearch.com